Incyte (NASDAQ:INCY) Given Hold Rating at Mizuho

Share on StockTwits

Mizuho restated their hold rating on shares of Incyte (NASDAQ:INCY) in a research report sent to investors on Thursday, AnalystRatings.com reports. They currently have a $79.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on INCY. JPMorgan Chase & Co. reiterated a buy rating on shares of Incyte in a research note on Tuesday, January 14th. JMP Securities reiterated an outperform rating and set a $121.00 target price on shares of Incyte in a research note on Tuesday, January 14th. Guggenheim downgraded Incyte from a buy rating to a neutral rating in a research note on Thursday, January 2nd. Evercore ISI reiterated a buy rating and set a $92.00 target price on shares of Incyte in a research note on Monday, January 27th. Finally, Credit Suisse Group reduced their target price on Incyte from $90.00 to $86.00 and set a neutral rating for the company in a research note on Friday, January 3rd. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Incyte has an average rating of Hold and an average target price of $91.45.

Shares of NASDAQ INCY traded up $0.40 during midday trading on Thursday, hitting $78.45. 1,370,174 shares of the company’s stock were exchanged, compared to its average volume of 1,612,612. The company has a quick ratio of 5.01, a current ratio of 5.02 and a debt-to-equity ratio of 0.02. Incyte has a 12 month low of $71.84 and a 12 month high of $96.79. The company’s 50 day moving average price is $78.56 and its 200 day moving average price is $82.10. The firm has a market capitalization of $16.81 billion, a PE ratio of 42.18, a price-to-earnings-growth ratio of 0.84 and a beta of 1.06.

Incyte (NASDAQ:INCY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.08. Incyte had a return on equity of 20.07% and a net margin of 19.21%. The company had revenue of $579.40 million during the quarter, compared to the consensus estimate of $558.13 million. During the same period in the previous year, the company posted $0.40 EPS. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, equities research analysts anticipate that Incyte will post 2.14 EPS for the current year.

In related news, EVP Yao Wenqing sold 3,165 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $95.00, for a total value of $300,675.00. Following the completion of the sale, the executive vice president now directly owns 98,473 shares in the company, valued at approximately $9,354,935. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul Trower sold 15,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $93.76, for a total value of $1,406,400.00. Insiders sold a total of 42,142 shares of company stock valued at $3,931,005 over the last 90 days. 17.10% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INCY. Savior LLC acquired a new position in Incyte in the 4th quarter valued at $27,000. Huntington National Bank acquired a new position in Incyte in the 4th quarter valued at $28,000. Advisory Alpha LLC raised its holdings in Incyte by 2,122.2% in the 4th quarter. Advisory Alpha LLC now owns 400 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 382 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Incyte by 617.7% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 445 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 383 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Incyte by 134.0% in the 4th quarter. Parallel Advisors LLC now owns 468 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 268 shares in the last quarter. Institutional investors and hedge funds own 91.06% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Recommended Story: What member countries make up the G-20?

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.